Technical Analysis for CRBU - Caribou Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Centerline Cross | Bullish | 0.00% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | 12.76% | |
50 DMA Support | Bullish | 12.76% | |
Bollinger Band Squeeze | Range Contraction | 12.76% |
Alert | Time |
---|---|
Possible Pocket Pivot | about 19 hours ago |
Up 2 ATRs | about 22 hours ago |
2x Volume Pace | about 23 hours ago |
1.5x Volume Pace | about 23 hours ago |
60 Minute Opening Range Breakout | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.33 |
52 Week Low | 1.5 |
Average Volume | 934,598 |
200-Day Moving Average | 3.45 |
50-Day Moving Average | 1.96 |
20-Day Moving Average | 1.93 |
10-Day Moving Average | 1.94 |
Average True Range | 0.14 |
RSI (14) | 64.16 |
ADX | 13.18 |
+DI | 30.99 |
-DI | 14.16 |
Chandelier Exit (Long, 3 ATRs) | 1.81 |
Chandelier Exit (Short, 3 ATRs) | 2.17 |
Upper Bollinger Bands | 2.12 |
Lower Bollinger Band | 1.73 |
Percent B (%b) | 1.24 |
BandWidth | 20.03 |
MACD Line | 0.02 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0251 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.62 | ||||
Resistance 3 (R3) | 2.58 | 2.41 | 2.55 | ||
Resistance 2 (R2) | 2.41 | 2.31 | 2.43 | 2.52 | |
Resistance 1 (R1) | 2.31 | 2.24 | 2.36 | 2.35 | 2.50 |
Pivot Point | 2.14 | 2.14 | 2.17 | 2.16 | 2.14 |
Support 1 (S1) | 2.04 | 2.04 | 2.09 | 2.08 | 1.92 |
Support 2 (S2) | 1.87 | 1.97 | 1.89 | 1.90 | |
Support 3 (S3) | 1.77 | 1.87 | 1.87 | ||
Support 4 (S4) | 1.81 |